Opinion|Videos|January 30, 2025
FDA-Approved IV Iron Formulations
Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and iron sucrose, offer improved safety profiles and more efficient iron delivery compared with older compounds, thanks to their more stable carbohydrate shells and controlled iron release mechanisms.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Could you provide an overview of the FDA-approved IV iron formulations used in the treatment of IDA? Additionally, what are the structural differences between the older and newer IV iron formulations?
Advertisement
Related to this article
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
IVF Beats IUI for Early Live Births in Unexplained Infertility
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5